Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open label, prospective, non-comparative, multicentre study to assess the safety and efficacy of Etanercept for injection 25 mg in patients with moderate to severe active rheumatoid arthritis.

Next Previous
Search
Trial Profile

An open label, prospective, non-comparative, multicentre study to assess the safety and efficacy of Etanercept for injection 25 mg in patients with moderate to severe active rheumatoid arthritis.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 29 Aug 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Etanercept (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use

    • Most Recent Events

    • 06 Mar 2011 Status changed from active, no longer recruiting to completed as reported by Clinical Trials Registry - India.
    • 24 Jul 2010 Status changed from recruiting to active, no longer recruiting as reported by Clinical Trials Registry - India record.
    • 08 Feb 2010 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top